||NT3 is a member of the neurotrophin family, that controls survival and differentiation of visceral and proprioceptive sensory neurons. NT3 is closely related to both NGF and BDNF. It may be involved in the maintenance of the adult nervous system, and may affect development of neurons in the embryo when it is expressed in human placenta. NT3-deficient mice generated by gene targeting display sevvere movement defects of the limbs. The mature peptide of this protein is identical in all mammals examined including human, pig, rat and mouse. SUBCELLULAR LOCATION: Secreted protein. TISSUE SPECIFICITY: Brain and peripheral tissues. SIMILARITY: Belongs to the NGF-beta family.
||See product label
||Recombinant human NT3
||Neurotrophin-3; Neurotrophic factor; HDNF; Nerve growth factor 2; NGF-2; Ntf3; Ntf-3
||Protein G purified IgG
||IHC, ELISA, WB, inhibition of biological activity. A concentration of 1-10 ug/mL is recommended for IHC, ELISA, WB and inhibition of biological activity in vitro; 2-10 ug/mL (ED50) for in vivo use. This antiserum will neutralise NT3 but not other neurotrophins. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
||A cross reactivity of less than 1% to mouse NGF, recombinant human BDNF and 5% to NT4/5 has been shown by 1-site ELISA.
||This antiserum is known to react with rat, chicken and human NT3.
||If you would like to see the shared identity between different species or other proteins follow the link in Accession field, select then the sequence (make sure that you are selecting the sequence that you are interested in, as the sequence may be the precursor rather than the mature protein for example) and copy and paste it HERE and blast/format it.
||Reconstitute in 500 uL of sterile water. Centrifuge to remove any insoluble material.
||After reconstitution keep aliquots at -20C for a higher stability, and at 2-8C with an appropriate antibacterial agent. Glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles.
||12 months after purchase
||1. Zouh et al. (1996) Mol. Neurobio. 13(3): 185-97
2. Rush et al. (1997) Clin. Exp. Pharmacol. 24: 549-55
3. Tafreshi et al. (1998) Neurosci. 83(2): 373-80